Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05638737 · ClinicalTrials.gov registry record · Phase 2
A Study in Participants With Non-cirrhotic NASH With Fibrosis
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT05638737 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 112 participants.
The verdict
NCT05638737, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. Participants will be in the trial for up to 24 weeks, including a screening period lasting up to 8 weeks, a 12-week treatment period, and a 4-week safety follow-up period Participants are not expected to directly benefit from treatment during this trial. Participants will help researchers learn more about and how to develop AZD4831 to treat NASH.
Interventions
- OTHER Placebo
- DRUG AZD4831
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2022-10-26 |
| Est. Completion | 2024-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05638737
The ClinicalTrials.gov registry entry for NCT05638737 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05638737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05638737 about?
NCT05638737 is a clinical study titled "A Study in Participants With Non-cirrhotic NASH With Fibrosis". This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. Participants will be in the trial for up to 24 weeks, including a screening period lasting up to 8 weeks, a 12-week treatment period, and a 4-week safety follow-up period Participants are not expected to dire...
What is the current status of trial NCT05638737?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2022-10-26. Estimated completion is 2024-04-04.
What interventions are being tested in trial NCT05638737?
The interventions under investigation include: Placebo (OTHER), AZD4831 (DRUG).
Who is sponsoring clinical trial NCT05638737?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.